{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"76","value":"47"},{"groupId":"OG001","lowerLimit":"34","upperLimit":"81","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Acute graft versus host disease is graded according to the 1994 Keystone Consensus Grading. aGVHD grade was evaluated from day 0 through 100 days post-transplant. The first day of acute GVHD onset at grades 2-4 was used to calculate the cumulative incidence. Relapse/death prior to onset was considered competing events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan Hydrochloride: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV","id":"OG000","title":"Regimen A (Fludarabine, Melphalan, PBSC HCT, GVHD Prophylaxis)"},{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV\n\nTotal-Body Irradiation: Undergo TBI","id":"OG001","title":"Regimen C (Fludarabine, TBI, PBSC HCT, GVHD Prophylaxis)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 100 days post-stem cell infusion","title":"Acute Graft Versus Host Disease (aGVHD) of Grades 2-4 According to the Consensus Grading","type":"SECONDARY","unitOfMeasure":"percentage of probability"}